Tolerance and Effect on Intraocular Pressure After Administration of SYL040012
Summary
The purpose of this study is to determine whether SYL040012 is safe for the treatment of ocular hypertension and glaucoma.
Study Design
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Conditions
Ocular Hypertension
Intervention
SYL040012
Location
Clínica Universitaria de Navarra
Pamplona
Navarra
Spain
31008
Status
Recruiting
Source
Sylentis, S.A.
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00990743
- Information obtained from ClinicalTrials.gov on July 15, 2010
Published on BioPortfolio: 2014-08-27T03:18:51-0400
Clinical Trials
SYL040012, Treatment for Open Angle Glaucoma
The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared ...
Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension
To evaluate if preservative free cosopt is well tolerated in patients with Open angle glaucoma (OAG) or Ocular hypertension (OH) with dry eyes.
A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma
The purpose of this study is to determine if the clinical profile of topical-ocular MGV354 merits further development for the indication of lowering intraocular pressure (IOP).
The primary objectives of this study are to compare the safety, tolerability, and mean change from baseline in diurnal intraocular pressure (IOP) of ONO-9054 30 µg/mL (0.003%) to latanopr...
A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom
Study PhXA41 for its non-inferiority compared with timolol in lowering intra-ocular pressure
PubMed Articles
What we have learned from the Ocular Hypertension Treatment Study.
To utilize results from the Ocular Hypertension Study that can aid patients and clinicians to make evidence based decisions about the management of ocular hypertension DESIGN: 1636 participants with o...
Prevalence of Ocular Hypertension and Glaucoma as well as Associated Factors in Graves' Orbitopathy.
To determine the prevalence of ocular hypertension (OHT) and open-angle glaucoma (OAG) in patients with GO and to investigate the associations between clinical features of the disease and the prevalen...
To assess mitochondrial dysfunction in vivo in ocular hypertension (OHT) and primary open-angle glaucoma (POAG) using retinal metabolic analysis.
The purpose of this study is to investigate the potential therapeutic benefits of intravitreally transplanted human umbilical cord mesenchymal stem cells (UC-MSCs) in an animal model of microbead-inje...
The article Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension, written by Sheridan Hoy, was originally published Online First without open access...
Medical and Biotech [MESH] Definitions
Paraneoplastic Syndromes, Ocular
Ocular manifestations secondary to various NEOPLASMS in which antibodies to antigens of the primary tumor cross-react with ocular antigens. This autoimmune response often leads to visual loss and other ocular dysfunctions.
Ocular Hypertension
A condition in which the intraocular pressure is elevated above normal and which may lead to glaucoma.
Travoprost
A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.
Accommodation, Ocular
The dioptric adjustment of the EYE (to attain maximal sharpness of retinal imagery for an object of regard) referring to the ability, to the mechanism, or to the process. Ocular accommodation is the effecting of refractive changes by changes in the shape of the CRYSTALLINE LENS. Loosely, it refers to ocular adjustments for VISION, OCULAR at various distances. (Cline et al., Dictionary of Visual Science, 4th ed)
Bimatoprost
A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.
